Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 20, 2019
Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), ...
February 20, 2019
Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme
NEW YORK and COLUMBUS, Ohio, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies ...
February 20, 2019
Genkyotex to Present Corporate Overview at Two Upcoming NASH Conferences
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that members of management ...
February 20, 2019
Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2018 Financial Results and Provide Corporate Update on February 26
SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) will announce its fourth quarter and full-year 2018 financial results on Tuesday, February 26, 2019, ...
February 20, 2019
HTG Molecular Announces an Amendment and Extension to its Precision Diagnostic Partnership (PDP) Two
TUCSON, Ariz., Feb. 20, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today ...
February 20, 2019
Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address ...
February 20, 2019
Achaogen Announces Closing of $15 Million Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address ...
February 19, 2019
Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis
Daix (France), February 18, 2019 - Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas ...
February 19, 2019
Basilea reports strong revenue growth and significant pipeline progress for full-year 2018
Basel, Switzerland, February 19, 2019 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today its financial results for the year 2018. ...
February 19, 2019
Saniona Tesomet Phase 2a Prader-Willi syndrome trial update
Saniona (SANION.ST), a biotech company focused on CNS and eating disorders, today reported an update on its ongoing dose-finding Phase 2a study of Tesomet in ...
February 19, 2019
RedHill Biopharma to Present at the 8th Annual SVB Leerink Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
February 19, 2019
InspireMD Announces Fourth Quarter 2018 Financial Results
TEL AVIV, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention ...
February 19, 2019
Aptose to Present at the 8th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO and TORONTO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that ...
February 19, 2019
VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26
TEL AVIV, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announces that the Company will present new data on the potential ...
February 19, 2019
Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell ...
February 19, 2019
CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
NEWARK, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), today announced the early completion of enrollment in a Phase 2b dose-ranging, paired ...
February 19, 2019
Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), ...
February 19, 2019
electroCore and HealthyWomen Announce Partnership on Patient Program to Increase Awareness of Non-Drug Migraine Therapies
BASKING RIDGE, N.J. and NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced a patient education ...
February 19, 2019
Pfenex Announces FDA Acceptance of NDA for PF708
SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
February 19, 2019
Theravance Biopharma to Report Fourth Quarter and Full Year 2018 Financial Results on February 26
DUBLIN, Feb. 19, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ...
Page 31 of 158